Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Thursday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Stock Up 3.1 %

Shares of NASDAQ:AEMD opened at $0.61 on Thursday. The stock’s 50 day moving average is $0.42 and its 200-day moving average is $0.43. The firm has a market capitalization of $8.46 million, a price-to-earnings ratio of -0.21 and a beta of 1.79. Aethlon Medical has a twelve month low of $0.24 and a twelve month high of $2.35.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.